CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer


Esteva F. J. , Wang J., Lin F., Mejia J. A. , Yan K., Altundag K., ...Daha Fazla

BREAST CANCER RESEARCH, cilt.9, sa.6, 2007 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Konu: 6
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1186/bcr1836
  • Dergi Adı: BREAST CANCER RESEARCH

Özet

Introduction We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC).